Abstract: A method of targeting extracellular vesicles employing a molecule comprising a GLA domain and extracellular vesicles obtained or obtainable from a method are described herein.
Type:
Grant
Filed:
September 5, 2018
Date of Patent:
May 14, 2024
Assignee:
GLADIATOR BIOSCIENCES, INC.
Inventors:
Terry Hermiston, Maxine Bauzon, Christopher H. Contag, Jonathan Hardy, Masamitsu Kanada
Abstract: The disclosure relates to the recombinant Gla domain proteins and their use targeting phosphatidylserine (PtdS) moieties on the surface of cells, particularly those expressing elevated levels of PtdS, such as cells undergoing apoptosis. These proteins can be linked to both diagnostic and therapeutic payloads, thereby permitting identification and treatment of cells expression elevated PtdS.
Abstract: The present disclosure relates to a method of targeting extracellular vesicles employing a molecule comprising a GLA domain and extracellular vesicles obtained or obtainable from a method disclosed herein.
Type:
Application
Filed:
September 5, 2018
Publication date:
March 4, 2021
Applicant:
GLADIATOR BIOSCIENCES, INC.
Inventors:
Terry HERMISTON, Maxine BAUZON, Christopher H. CONTAG, Jonathan HARDY, Masamitsu KANADA
Abstract: The disclosure relates to the recombinant Gla domain proteins and their use targeting phosphatidylserine (PtdS) moieties on the surface of cells, particularly those expressing elevated levels of PtdS, such as cells undergoing apoptosis.
Abstract: The disclosure relates to the recombinant Gla domain proteins and their use targeting phosphatidylserine (PtdS) moieties on the surface of cells, particularly those expressing elevated levels of PtdS, such as cells undergoing apoptosis.
Abstract: The disclosure relates to the recombinant Gla domain proteins and their use targeting phosphatidylserine (PtdS) moieties on the surface of cells, particularly those expressing elevated levels of PtdS, such as cells undergoing apoptosis. These proteins can be linked to both diagnostic and therapeutic payloads, thereby permitting identification and treatment of cells expression elevated PtdS.
Abstract: The present disclosure relates to a method of targeting stems cells, in particular non-apoptotic stem cells, employing a GLA domain, capable of binding surface exposed phosphatidyl serine.
Type:
Application
Filed:
September 5, 2018
Publication date:
December 31, 2020
Applicant:
GLADIATOR BIOSCIENCES, INC.
Inventors:
Terry HERMISTON, Maxine BAUZON, Christopher H. CONTAG, Jonathan HARDY, Francis Gerard BLANKENBERG
Abstract: The disclosure relates to the recombinant Gla domain proteins and their use targeting phosphatidylserine (PtdS) moieties on the surface of cells, particularly those expressing elevated levels of PtdS, such as cells undergoing apoptosis.